Supplementary Figure 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Key Points

MAIN FINDING: The tumor microenvironment (TME) varies significantly among patients with liver metastases.
KEY EVIDENCE: Supplemental figure outlines differences in TME characteristics linked to nivolumab and relatlimab treatment.
APPROACH: Analysis involved comparing liver metastases TME features from multiple colorectal cancer patients.
SIGNIFICANCE: Understanding the TME can enhance treatment strategies for colorectal cancer patients with specific profiles.

Supplementary figure compares tumor microenvironment of liver metastases in colorectal cancer patients, indicating treatment variability.

Supplementary Figure 2. Comparison of the tumor microenvironment (TME) of liver metastases across patients.

No takes yet. Share an insight, caveat, or question.

Christenson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share